Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis

Part of paid clinical trials in Encino, California.

Sponsor
Organon and Co
Study ID
NCT04042103
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in adults with plaque psoriasis.

Key Dates

Start date
Jul 23, 2019
Status verified
May 2022
Primary completion
Jan 9, 2020
Completion
Jan 9, 2020

Study Design

Enrollment
21 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Tapinarof (DMVT-505) cream, 1%
    Tapinarof (DMVT-505) cream, 1% applied topically once daily

Primary Outcome Measure

Number of Participants That Experienced Adverse Events (AEs), Severe Adverse Events, and Serious Adverse Events (SAEs) [ Time Frame: Baseline to Week 4 ]

Locations (6)

FacilityCityStateZIPSite coordinators
Dermavant Investigational SiteEncinoCalifornia91436-
Dermavant Investigational SiteSanfordFlorida32771-
Dermavant Investigational SitePhiladelphiaPennsylvania19103-
Dermavant Investigational SiteAustinTexas78759-
Dermavant Investigational SiteSan AntonioTexas78213-
Dermavant Investigational SiteSpokaneWashington99202-

Find similar trials in Encino, CA

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Dermavant Investigational Site· Encino, CADermavant Investigational Site· Sanford, FLDermavant Investigational Site· Philadelphia, PADermavant Investigational Site· Austin, TXDermavant Investigational Site· San Antonio, TXDermavant Investigational Site· Spokane, WA

Related Studies